PRIMAL STUDY: A Phase 1b, Open-label, Multicenter, Multinational Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel (PDoc) in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Trial Profile

PRIMAL STUDY: A Phase 1b, Open-label, Multicenter, Multinational Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel (PDoc) in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 May 2017

At a glance

  • Drugs Hyaluronidase (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms PRIMAL
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 04 May 2017 Status changed from active, no longer recruiting to discontinued.
    • 12 Oct 2016 Planned End Date changed from 1 Feb 2018 to 1 Mar 2017.
    • 12 Oct 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top